Jefferies maintained a buy rating on Godrej Properties post Q3 results but raised the target price to Rs 2700 from Rs 2635. “Sales surge preceding margin jump. The company reported back-to-back record pre-sales quarters and a strong launch pipeline for Q4,” Jefferies said.
Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in Brazil
Biocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis received full allocation under the